FENC vs. AVXL, OPT, SANA, LENZ, RLAY, IMTX, CGEM, AUTL, VALN, and TECX
Should you be buying Fennec Pharmaceuticals stock or one of its competitors? The main competitors of Fennec Pharmaceuticals include Anavex Life Sciences (AVXL), Opthea (OPT), Sana Biotechnology (SANA), LENZ Therapeutics (LENZ), Relay Therapeutics (RLAY), Immatics (IMTX), Cullinan Therapeutics (CGEM), Autolus Therapeutics (AUTL), Valneva (VALN), and Tectonic Therapeutic (TECX). These companies are all part of the "biological products, except diagnostic" industry.
Fennec Pharmaceuticals vs.
Anavex Life Sciences (NASDAQ:AVXL) and Fennec Pharmaceuticals (NASDAQ:FENC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, community ranking, earnings, valuation and profitability.
In the previous week, Anavex Life Sciences had 12 more articles in the media than Fennec Pharmaceuticals. MarketBeat recorded 12 mentions for Anavex Life Sciences and 0 mentions for Fennec Pharmaceuticals. Anavex Life Sciences' average media sentiment score of 0.90 beat Fennec Pharmaceuticals' score of 0.00 indicating that Anavex Life Sciences is being referred to more favorably in the media.
31.6% of Anavex Life Sciences shares are held by institutional investors. Comparatively, 55.5% of Fennec Pharmaceuticals shares are held by institutional investors. 11.0% of Anavex Life Sciences shares are held by company insiders. Comparatively, 11.0% of Fennec Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Fennec Pharmaceuticals has higher revenue and earnings than Anavex Life Sciences. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Anavex Life Sciences, indicating that it is currently the more affordable of the two stocks.
Anavex Life Sciences has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500. Comparatively, Fennec Pharmaceuticals has a beta of 0.34, indicating that its share price is 66% less volatile than the S&P 500.
Anavex Life Sciences received 239 more outperform votes than Fennec Pharmaceuticals when rated by MarketBeat users. Likewise, 74.79% of users gave Anavex Life Sciences an outperform vote while only 66.45% of users gave Fennec Pharmaceuticals an outperform vote.
Anavex Life Sciences presently has a consensus price target of $44.00, suggesting a potential upside of 426.95%. Fennec Pharmaceuticals has a consensus price target of $13.67, suggesting a potential upside of 105.51%. Given Anavex Life Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Anavex Life Sciences is more favorable than Fennec Pharmaceuticals.
Anavex Life Sciences has a net margin of 0.00% compared to Fennec Pharmaceuticals' net margin of -2.30%. Anavex Life Sciences' return on equity of -37.50% beat Fennec Pharmaceuticals' return on equity.
Summary
Anavex Life Sciences beats Fennec Pharmaceuticals on 11 of the 17 factors compared between the two stocks.
Get Fennec Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for FENC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fennec Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:FENC) was last updated on 2/22/2025 by MarketBeat.com Staff
